Certara Brand Guidelines: Tripos, Pharsight, Simcyp & the Business of Biosimulation

A chemistry-software pioneer meets a modelling firm.

Certara was put together from two older software companies. In September 2008 Tripos, then wholly owned by the San Francisco private-equity firm Vector Capital, agreed to acquire Pharsight, Drug Discovery & Development reported, with the deal expected to close in the fourth quarter of that year; the combined business was to offer software products and scientific services. Certara says that in 2008 Tripos International and Pharsight Corporation “came together to form Certara,” and on its timeline it dates Tripos’s computational drug-discovery work to 1979 and Pharsight’s modelling business to 1995.

The next step defined the company. On 13 March 2012 Certara acquired Simcyp of Sheffield, England, according to English Wikipedia, which describes Simcyp as a spin-out from the University of Sheffield that makes modelling and simulation software for drug development. Certara’s own timeline places physiologically based pharmacokinetic modelling, which simulates how a drug moves through virtual patient populations, in that year.

Ownership changed hands among investors. Certara’s 2020 registration statement with the U.S. Securities and Exchange Commission says the present parent, Certara, Inc., was incorporated in Delaware in June 2017, and that in August 2017 funds affiliated with the investment firm EQT acquired most of the company’s equity from affiliates of Arsenal Capital Partners and other holders. The same filing says Certara had by then acquired twelve companies, nine of them involving software or technology, and calls Simcyp the core of its mechanistic biosimulation platform.

Simulation, analysis and regulatory data.

Certara works in what the industry calls model-informed drug development: using mathematical models of how drugs behave in the body to inform choices about dosing, trial design and regulatory submissions. Its business has two sides, software and scientific services, and its press releases describe it as using biosimulation software, technology and services to transform traditional drug discovery and development.

The software range in 2026 is broad. Certara’s website lists Phoenix, for pharmacokinetic, pharmacodynamic and toxicokinetic analysis and modelling; the Simcyp simulator, for physiologically based modelling of drug behaviour in diverse populations; Pinnacle 21, for standardising and validating clinical data; and D360, for scientific informatics on molecules and bioactivity. Further names on the list include Certara.AI, a platform the company describes as designed for life sciences, and tools for regulatory submissions and value communication.

Simcyp carries its own scientific network. English Wikipedia says Simcyp operates the Simcyp Consortium of pharmaceutical and biotechnology companies, which acts as a steering committee for its research, and that work within the consortium’s framework includes collaboration with regulators such as the U.S. Food and Drug Administration. Wikipedia names simulator platforms for paediatric populations and for laboratory species as well as the main population-based simulator.

Chemistry came back into the company in 2024. On 2 October 2024 Certara announced that it had completed the acquisition of Chemaxon, a maker of cheminformatics software whose products include Design Hub and JChem Engines; the release said the near-term plan was to bring Chemaxon’s chemical structures, calculators and predictors into D360 and the Simcyp simulator, and Chemaxon’s chief executive, Richard Jones, said accurate scientific prediction and biosimulation mattered more as pipelines shifted towards precision-medicine therapies. In its 2026 releases the company says its clients include more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Software for the lab and the clinic.

Life-sciences software is sold to scientists, clinicians, regulators and procurement teams at once, and the way these companies present themselves reflects that mixed audience. Their websites and brochures tend to show clean dashboards on laptops and tablets, molecule renderings and data charts, and people in lab coats or at clinic desks looking at screens. The product, in other words, is usually shown as an interface rather than an object.

The colour schemes follow the same logic. Many of these brands set one or two bright product colours against a lot of white space, so that charts, buttons and status labels stand out, and they use plain sans-serif type that stays legible in dense tables. Product families are often split into named “clouds,” “suites” or “platforms,” each with its own sub-brand, so a single company can carry dozens of product names under one mark.

Much of the selling happens in person. The sector gathers at trade conferences such as the DIA Global Annual Meeting, which brings together people working on drug development and regulation; Bio-IT World, which focuses on data and computing in life-sciences research; and SLAS, the laboratory-automation and screening society’s conference. Larger vendors also run their own customer summits, with keynote stages, product launches and user sessions; Medidata, for example, says its NEXT conference grew out of a user group for its Rave software.

Ownership matters too: several of the companies in this round have changed hands, and some have been bought by larger groups while keeping their own names. The guides in this round set out who founded each company, who owns it now and what it makes, and they mark clearly which statements rest only on the company’s own word.

From a private-equity group to Nasdaq.

Certara became a public company in December 2020. EQT announced on 17 December that year that Certara had priced its initial public offering on 10 December, that its shares had begun trading on the Nasdaq Global Select Market under the ticker CERT on 11 December, and that the offering had closed on 15 December; EQT said it was its first initial public offering in the United States, and that its fund kept roughly half of the company after the listing. At that point EQT described Certara’s clients as about 1,600 biopharmaceutical companies, academic institutions and regulators in 60 countries, and the registration statement put the company’s workforce at about 900 people.

The address on the company’s news has moved. The 2020 registration statement gave Certara’s principal executive offices as Princeton, New Jersey; its releases since at least October 2024, including the Chemaxon announcement, are datelined Radnor, Pennsylvania.

2026 brought a change of shape. On 22 April 2026 Certara announced a definitive agreement to sell its Regulatory Writing and Medical Writing business, a unit of about 220 people, to Veristat, with chief executive Jon Resnick saying the company’s strategy was centred on its model-informed drug development and clinical intelligence offerings. In its second-quarter results on 4 August 2026, Certara said it had completed that divestiture and set up two new business units. The company describes itself as a global leader in model-informed drug development; that is its own claim.

For a design guide, Certara shows how a company assembled from several acquisitions can present one scientific brand while keeping well-known product names such as Simcyp and Phoenix in view. Compare Simulations Plus, another maker of drug-development modelling software, and Schrödinger, a computational chemistry company. For this guide we use a deep navy, a dark violet and a warm amber with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Certara’s identity on hand — save it to a board in the Made Good inspiration library.